Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • « Prev · Page [28]
NCT ID: NCT00747396 Active, not recruiting - Health Behavior Clinical Trials

The Bucharest Early Intervention Project

BEIP
Start date: September 2000
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the long term effects of early intervention (placement into foster care) on physical, cognitive, social and brain development and psychiatric symptomatology in previously institutionalized children.

NCT ID: NCT00718484 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

PICASSO
Start date: August 2008
Phase: Phase 2
Study type: Interventional

This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS). Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will be anthracyclin naïve.

NCT ID: NCT00715637 Active, not recruiting - Clinical trials for Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Start date: June 2007
Phase: Phase 3
Study type: Interventional

Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML.

NCT ID: NCT00622700 Active, not recruiting - Multiple Sclerosis Clinical Trials

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

TOPIC
Start date: February 2008
Phase: Phase 3
Study type: Interventional

The primary objective is to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS). The secondary objectives are: - To demonstrate the effect of teriflunomide, in comparison to placebo, on: - Reducing conversion to definite multiple sclerosis (DMS) - Reducing annualized relapse rate (ARR) - Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI) - Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS) - Proportion of disability-free participants as assessed by the EDSS - Reducing participant-reported fatigue - To evaluate the safety and tolerability of teriflunomide - To evaluate the pharmacokinetics (PK) of teriflunomide - Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes

NCT ID: NCT00465491 Active, not recruiting - Clinical trials for Small Cell Lung Cancer

Study of Picoplatin Efficacy After Relapse

SPEAR
Start date: April 2007
Phase: Phase 3
Study type: Interventional

Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options. This study is designed to compare the efficacy and safety of picoplatin plus Best Supportive Care (BSC) with BSC alone. Best Supportive Care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side-effects of anti-cancer treatments.

NCT ID: NCT00410761 Active, not recruiting - Thyroid Cancer Clinical Trials

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Start date: November 30, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

NCT ID: NCT00122811 Active, not recruiting - Hypertension Clinical Trials

The Hypertension in the Very Elderly Trial (HYVET)

Start date: November 2000
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.

NCT ID: NCT00022516 Active, not recruiting - Breast Cancer Clinical Trials

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

22-00
Start date: November 2000
Phase: Phase 3
Study type: Interventional

This randomized, phase III trial was designed to test the efficacy of a low-dose chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered following standard chemotherapy in patients with early breast cancer whose tumors are hormone receptor negative.